Rodriguez E , et al.. Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? Clin Kidney J 2017; 10:320–322. doi: 10.1093/ckj/sfx024

• PubMed
Rodriguez E , . Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? Clin Kidney J 2017; 10:320–322. doi: 10.1093/ckj/sfx024 )| false
• Search Google Scholar
• Export Citation

Skoczynska M , et al.. Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: Case report and systematic review of the literature. Lupus 2020; 29:631–639. doi: 10.1177/0961203320917460

• PubMed
Skoczynska M , . Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: Case report and systematic review of the literature. Lupus 2020; 29:631–639. doi: 10.1177/0961203320917460 )| false
• Search Google Scholar
• Export Citation

Nakamura H , et al.. Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy: A case report successfully treated with eculizumab. Nephron 2018; 138:324–327. doi: 10.1159/000485194

• PubMed
Nakamura H , . Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy: A case report successfully treated with eculizumab. Nephron 2018; 138:324–327. doi: 10.1159/000485194 )| false
• Search Google Scholar
• Export Citation

Palomo M , et al.. Complement activation and thrombotic microangiopathies. Clin J Am Soc Nephrol 2019; 14:1719–1732. doi: 10.2215/CJN.05830519

• PubMed
Palomo M , . Complement activation and thrombotic microangiopathies. Clin J Am Soc Nephrol 2019; 14:1719–1732. doi: 10.2215/CJN.05830519 )| false
• Search Google Scholar
• Export Citation

Ariceta G , et al.. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int [published online ahead of print December 8, 2020]. doi: 10.1016/j.kint.2020.10.046; https://www.kidney-international.org/article/S0085-2538(20)31418-6/fulltext

• PubMed
Ariceta G , . The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int [published online ahead of print December 8, 2020]. doi: 10.1016/j.kint.2020.10.046; https://www.kidney-international.org/article/S0085-2538(20)31418-6/fulltext )| false
• Search Google Scholar
• Export Citation

Jayne DRW , et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017; 28:2756–2767. doi: 10.1681/ASN.2016111179

• PubMed
Jayne DRW , . Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017; 28:2756–2767. doi: 10.1681/ASN.2016111179 )| false
• Search Google Scholar
• Export Citation

Jayne DRW , et al.. ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384:599–609. doi: 10.1056/NEJMoa2023386

• PubMed
Jayne DRW , . ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384:599–609. doi: 10.1056/NEJMoa2023386 )| false
• Search Google Scholar
• Export Citation

Merkel PA , et al.. Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: Protocol for a randomized, double-blind, active-controlled, phase 3 trial. JMIR Res Protoc 2020; 9:e16664. doi: 10.2196/16664

• PubMed
Merkel PA , . Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: Protocol for a randomized, double-blind, active-controlled, phase 3 trial. JMIR Res Protoc 2020; 9:e16664. doi: 10.2196/16664 )| false
• Search Google Scholar
• Export Citation